Polar Capital Holdings Plc Trims Holdings in Qiagen (NYSE:QGEN)

Polar Capital Holdings Plc lessened its holdings in Qiagen (NYSE:QGEN - Free Report) by 29.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 170,863 shares of the company's stock after selling 69,621 shares during the period. Polar Capital Holdings Plc owned about 0.08% of Qiagen worth $7,609,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. Brown Brothers Harriman & Co. purchased a new position in Qiagen in the 4th quarter valued at about $37,000. Geneos Wealth Management Inc. boosted its stake in shares of Qiagen by 41.5% in the fourth quarter. Geneos Wealth Management Inc. now owns 856 shares of the company's stock worth $38,000 after acquiring an additional 251 shares during the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Qiagen by 152.5% during the fourth quarter. EverSource Wealth Advisors LLC now owns 871 shares of the company's stock worth $39,000 after purchasing an additional 526 shares in the last quarter. Smartleaf Asset Management LLC increased its position in shares of Qiagen by 148.0% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the company's stock worth $63,000 after purchasing an additional 835 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB raised its stake in Qiagen by 83.5% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 1,565 shares of the company's stock valued at $70,000 after purchasing an additional 712 shares during the last quarter. Hedge funds and other institutional investors own 70.00% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. Redburn Atlantic cut shares of Qiagen from a "buy" rating to a "neutral" rating in a research note on Friday, April 4th. Baird R W lowered shares of Qiagen from a "strong-buy" rating to a "hold" rating in a research report on Wednesday, February 19th. Robert W. Baird increased their price objective on shares of Qiagen from $42.00 to $43.00 and gave the company a "neutral" rating in a report on Monday, April 21st. StockNews.com raised shares of Qiagen from a "buy" rating to a "strong-buy" rating in a research note on Thursday. Finally, UBS Group lowered their target price on Qiagen from $50.00 to $48.00 and set a "neutral" rating on the stock in a report on Friday, February 7th. Seven investment analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of "Hold" and an average target price of $48.42.

Qiagen Trading Up 0.3%

NYSE:QGEN traded up $0.12 on Monday, hitting $42.77. The stock had a trading volume of 1,572,493 shares, compared to its average volume of 1,146,855. The company has a fifty day moving average price of $41.03 and a two-hundred day moving average price of $41.82. Qiagen has a 1-year low of $37.63 and a 1-year high of $49.30. The company has a quick ratio of 3.09, a current ratio of 3.61 and a debt-to-equity ratio of 0.38. The stock has a market cap of $9.51 billion, a price-to-earnings ratio of 119.09, a PEG ratio of 2.39 and a beta of 0.67.

Qiagen (NYSE:QGEN - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.55 EPS for the quarter, beating the consensus estimate of $0.50 by $0.05. Qiagen had a net margin of 4.23% and a return on equity of 13.92%. The firm had revenue of $483.46 million for the quarter, compared to analyst estimates of $465.66 million. During the same quarter in the previous year, the company earned $0.44 EPS. The business's revenue for the quarter was up 5.2% compared to the same quarter last year. Equities research analysts expect that Qiagen will post 2.26 earnings per share for the current fiscal year.

Qiagen Company Profile

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. The company sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials.